13F data as of 2024-12-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

CUSIP

56854Q200

FAQ

Who are the top institutional investors holding MARINUS PHARMACEUTICALS INC (MRNS*)?

Major stakeholders currently include Beryl Capital Management LLC ($2.3M), Morgan Stanley ($1.8M), Oddo Bhf Asset Management Sas ($1.4M). Based on the latest 13F filings, there are a total of 54 tracked investment funds and institutions maintaining positions in MRNS*.

What is the overall institutional sentiment toward MRNS* recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $57.3M, driven by 8 managers accumulating shares while 10 reduced their exposure.

Which institutions have been selling or reducing their MRNS* positions?

In the latest period, 6 funds trimmed their holdings, and 4 managers completely exited their positions. The aggregate reported sell value was $11.3M.

Are there any notable investors adding MRNS* to their portfolios?

Yes, buying activity remains notable. 3 institutions opened new positions in {ticker}, and 5 existing holders added to their shares. The total reported buy value for the quarter amounted to $2.5M.